GLG News Analyses of the following article:
FDA Investigating Reports of Liver Injury in Patients Using Weight Loss Drug Orlistat
Published at: www.webmd.com
-
Unclear how orlistat's mechanism can lead to liver damage. Likely a non-issue.
August 28, 2009
Orlistat is designed to act peripherally in the GI tract and studies have demonstrated negligible systemic absorption of orlistat. Patients suffering from liver damage are either hypersensitive to orlistat or have taken too much of the drug. It is likely that these cases of liver injury are unrelated to orlistat, since obesity predisposes patients for liver damage. But overall cases of liver damage are small compared to the total number of patients who have taken the drug over the years.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.